Navigation Links
US Oncology Named to FORTUNE Magazine's Most Admired Companies List for Third Time
Date:3/12/2009

gy network were enrolled in clinical research trials across the nation. These services, as well as many others, are offered as an integrated solutions concept that serves the best interests of patients, practices and biotech/pharmaceutical partners.

About US Oncology

US Oncology, headquartered in the Houston area, works closely with physicians, payers, biotechnology, pharmaceutical and medical equipment manufacturers, to identify and deliver innovative services that enhance patient access to advanced cancer care. US Oncology supports one of the nation's foremost cancer treatment and research networks, accelerating the availability and use of evidence-based medicine and shared best practices.

US Oncology uses its expertise to support every aspect of the cancer care delivery system--from drug development to treatment and outcomes measurement--enabling the company to help increase the efficiency and safety of cancer care. According to the company's last quarterly earnings report, US Oncology is affiliated with 1,211 physicians operating in 456 locations, including 94 radiation oncology facilities in 39 states. For more information, visit the company's Web site, www.usoncology.com.


'/>"/>
SOURCE US Oncology, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Campbell Alliance Brand Management Practice to Present at EyeForPharmas Oncology Summit USA and Oncology Market Access Europe Conference
2. Micromet Adds Former Head of Roche Oncology Kapil Dhingra, MD to Board of Directors
3. Encorium Group Signs $3.1 Million of New Business Contracts Including an Extension of a Current U.S. Oncology Clinical Trial with a Major Pharmaceutical Company
4. Pharmatech 2.0: Introducing Pharmatech Oncology
5. Oncology Biomarker KRAS to be Discussed at FDA Panel Meeting
6. Spectrum Pharmaceuticals and Cell Therapeutics to Jointly Market ZEVALIN, a Proprietary, Marketed Oncology Drug
7. Varian Medical Systems Introducing OncoView(TM) - an Oncology Specific Image Management and Storage Solution
8. Debiopharm and Aurigene Sign Licensing Agreement for the Development and Commercialisation of Debio 0617, a Novel Inhibitor of an Undisclosed Oncology Pathway
9. Onyx Pharmaceuticals Licenses Rights to Novel Targeted Oncology Agent From BTG International
10. Radiation Therapy Oncology Group and US Oncology Enter Collaboration to Increase Patient Access to National Clinical Trials
11. First Coast Oncology to Offer Next Generation Proton Therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... One of the major revolutions taking place in healthcare ... practice of using genomic and other molecular analyses to ... diagnostics—laboratory analyses that inform the practice of personalized medicine—will ... fall, AACC ,s first ever virtual conference ... field and the novel technologies driving it forward, all ...
(Date:8/1/2014)... August 1, 2014 According to ... "Biophotonics Market - Global Industry Analysis, Size, Share, Growth, ... valued at USD 25.16 billion in 2013, which is ... at a CAGR of 10.4% from 2014 to 2020. ... http://www.transparencymarketresearch.com/biophotonics-market.html Increasing demand for accurate early ...
(Date:8/1/2014)... Toronto, Canada (PRWEB) August 01, 2014 ... what should it cost? This webinar will discuss how ... construction. , Join speakers Bob Allen, Senior Director ... Director of Process Engineering at Fluor Industrial Services, and ... supporting Manufacturing Asset Planning at Amgen, as they provide ...
(Date:8/1/2014)... RUTHERFORD, N.J., Aug. 1, 2014 Cambrex Corporation (NYSE: ... ended June 30, 2014. Highlights ... $61.6 million in the same period last year. , ... $11.4 million in the same period last year (see table ... 2014 sales guidance increased, excluding the impact of foreign currency, ...
Breaking Biology Technology:First-Ever AACC Virtual Conference to Focus on Personalized Diagnostics 2Global Biophotonics Market is Expected to Reach USD 50.20 Billion in 2020: Transparency Market Research 2Global Biophotonics Market is Expected to Reach USD 50.20 Billion in 2020: Transparency Market Research 3Global Biophotonics Market is Expected to Reach USD 50.20 Billion in 2020: Transparency Market Research 4Defining Low Cost in Your Solution for Future Facilities, New Webinar for Pharma, Biotech, Medical Device and Healthcare Companies, Hosted by Xtalks 2Cambrex Reports Second Quarter 2014 Financial Results 2Cambrex Reports Second Quarter 2014 Financial Results 3Cambrex Reports Second Quarter 2014 Financial Results 4Cambrex Reports Second Quarter 2014 Financial Results 5Cambrex Reports Second Quarter 2014 Financial Results 6Cambrex Reports Second Quarter 2014 Financial Results 7Cambrex Reports Second Quarter 2014 Financial Results 8Cambrex Reports Second Quarter 2014 Financial Results 9Cambrex Reports Second Quarter 2014 Financial Results 10Cambrex Reports Second Quarter 2014 Financial Results 11Cambrex Reports Second Quarter 2014 Financial Results 12Cambrex Reports Second Quarter 2014 Financial Results 13Cambrex Reports Second Quarter 2014 Financial Results 14Cambrex Reports Second Quarter 2014 Financial Results 15Cambrex Reports Second Quarter 2014 Financial Results 16
... Inc., a consulting firm,providing outcomes research and health ... announces the addition of,Anthony J. Vita, MD, MPH ... clinical,professionals. The specialized background of these two practitioners ... directly to those clients,seeking to enhance the clinical ...
... Palatin Technologies,Inc. (Amex: PTN ) will announce its ... 2007 before the open of the U.S. financial,markets. ... audio webcast,hosted by Palatin,s executive management team on November ... operations in greater detail and provide,an update on corporate ...
... SOUTH SAN FRANCISCO, Calif., Nov. 5 Exelixis,Inc. ... for the third quarter,ended September 30, 2007. ... were $26.8 million,compared to $23.5 million for the ... 2006 to 2007 was primarily due to revenue ...
Cached Biology Technology:EPI-Q, Inc. Expands Capabilities with Addition of Anthony Vita, MD, MPH and Peter Herout, PharmD 2Palatin Technologies to Report Fiscal Year 2008 First Quarter Results; Teleconference and Webcast on November 9, 2007 2Exelixis Announces Third Quarter 2007 Financial Results and Business Update 2Exelixis Announces Third Quarter 2007 Financial Results and Business Update 3Exelixis Announces Third Quarter 2007 Financial Results and Business Update 4Exelixis Announces Third Quarter 2007 Financial Results and Business Update 5Exelixis Announces Third Quarter 2007 Financial Results and Business Update 6Exelixis Announces Third Quarter 2007 Financial Results and Business Update 7Exelixis Announces Third Quarter 2007 Financial Results and Business Update 8
(Date:8/1/2014)... NY, August 1, 2014Lesbian, gay, bisexual, and transgender individuals ... same problems as some of their heterosexual and cisgendered ... often face additional physiological and legal challenges to ... advances in assisted reproduction options is presented in the ... Possibilities ," published in LGBT Health ...
(Date:8/1/2014)... eye diseases is tricky enough. Knowing what causes them ... Now, University of Iowa researchers have created the most ... human eye long associated with blinding diseases, such as ... of proteins in the choroid, which supplies blood and ... By seeing differences in the abundance of proteins in ...
(Date:8/1/2014)... Sieve elements are a key component of phloem, the ... wide range of signalling molecules. Elongated cylindrical cells are ... arranged end-to-end to form sieve tubes which in turn ... "Sieve elements are very special cells which play ... very little has been known about their differentiation," says ...
Breaking Biology News(10 mins):Advances in assisted reproduction create more options & new legal issues for LGBT couples 2A map for eye disease 2Developmental regulation of important plant phloem components discovered 2
... years, researchers have worked to develop a number of ... vaccines are not intended to prevent cancer; rather, they ... Unlike traditional chemotherapy, vaccines have relatively low toxicity and, ... these vaccines have rarely been designed to directly stimulate ...
... physics to show how our circadian clocks manage to ... , In an article appearing March 13 in the ... Federale de Lausanne demonstrate that the stability of cellular ... studies in families affected by advanced sleep phase syndrome. ...
... role in the development of the placenta, the organ that ... fetus during pregnancy, and perhaps in miscarriages. , Those ... gene in mice. In humans, this gene, when mutated, raises ... retinoblastoma. Two decades ago, it was identified as the first ...
Cached Biology News:Novel antigen-cloning technique may boost efforts to develop a melanoma vaccine 2Novel antigen-cloning technique may boost efforts to develop a melanoma vaccine 3Keeping the body in sync -- The stability of cellular clocks 2Tumor-suppressor gene is critical for placenta development 2Tumor-suppressor gene is critical for placenta development 3
, Premium quality synthesis and purification , You provide the sequence, we'll do the rest , Rigorous quality control , Your choice of purification method, amount and format , Available annealed...
... Synthetic peptide derived from an internal region ... target of rapamycin FRAP RAFT1 RAPT1). ... On Western blots it identifies the ... Human (positive control: HEK293 cell lysates). Based ...
...
From micro to giga sizes, from single prep to high-throughput, Invitrogen's range of plasmid purification kits offers superior performance to match the demands of your downstream application....
Biology Products: